Role of pantoprazole in the treatment of gastro-oesophageal reflux disease

Bibliography

• SIMON B, MUELLER P, PASCU 0 et al.: Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. (2003) 15:791–799.
   Google Scholar
• KOVACS TO, WILCOX CM, DE VAULT K, MISKA D, BOCHENEK W, and the PANTOPRAZOLE US GERD STUDY GROUP B: Comparison of the efficacy of pantoprazole versus nizatidine in the treatment of erosive oesophagitis: a randomised, active-controlled, double-blind study. Aliment. Pharmacol Ther. (2002) 16:2043–2052.
   PubMed Web of Science ®Google Scholar
• FLOCKHART DA, DESTA Z, MAHAL SK: Selection of drugs to treat gastro-oesophageal reflux disease. Clin. Pharmacokinet. (2000) 39:295–309.
   PubMed Web of Science ®Google Scholar
• REVICKI DA, WOOD M, MATON PN, SORENSEN S: The impact of gastroesophageal reflux disease on health-related quality of life. Am. J. Med. (1998) 104:252–258.
   PubMed Web of Science ®Google Scholar
• LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnnesota. Gastroenterology (1997) 112:1448–1456.
   PubMed Web of Science ®Google Scholar
• BELL NJ, BURGET D, HOWDEN CW, WILKINSON J, HUNT RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 51(S1):59–67.
   PubMedGoogle Scholar
• KATZ PO: Pathogenesis and management of gastroesophageal reflux disease. J. Clin. Gastroenterol (1991) 13(52):56–515. Gives important information on the prevalence of GERD.
   Google Scholar
• DETTMER A, VOGT R, SIELAFF F, LUHMANN R, SCHNEIDER A. FISCHER R: Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment. Pharmacol. Ther. (1998) 12:865–872.
   Google Scholar
• HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266–280.
   PubMed Web of Science ®Google Scholar
• JUNGNICKEL PW: Pantoprazole: a new proton pump inhibitor. Clin. Ther. (2000) 22:1268–1293.
   PubMed Web of Science ®Google Scholar
• SHIN JM, CHO YM, SACHS G: Chemistry of covalent inhibition of the gastric (H+,K+)-ATPase by proton pump inhibitors. J. Amer Chem Soc. (2004) 126:7800–7811.
   PubMed Web of Science ®Google Scholar
• AVNER DL: Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin. Ther. (2000) 22:1169–1185.
   PubMed Web of Science ®Google Scholar
• HUBER R, HARTMANN M, BLIESATH H, LUHMANN R, STEINIJANS VW, ZECH K: Pharmacokinetics of pantoprazole in man. Int. J. Clin. Pharmacol. Ther. (1996) 34:185–194.
   PubMed Web of Science ®Google Scholar
• PARSONS ME: Pantoprazole, a new proton pump inhibitor, has a precise and predictable profile of activity. Eur. GastroenteroL HepatoL (1996) 8(S1):S15–S20.
   Google Scholar
• TANAKA M, YAMAZAKI H, RYOKAWA Y, HAKUSUI H, NAKAMICHI N, SEKINO H: Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:415–419.
   PubMed Web of Science ®Google Scholar
• BLIESATH H, HUBER R, HARTMANN M, LUHMANN R, WURST W: Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Int. J. Clin. Pharmacol. Ther. (1994) 32:44–50.
   PubMedGoogle Scholar
• ANDERSSON T, HOLMBERG J, ROHSS K, WALAN A: Pharmacokinetics and effect on caffein metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br. J. Clin. Pharmacol. (1998) 45:369–375.
   PubMed Web of Science ®Google Scholar
• •Describes potential interactions of different PPIs with caffeine.
   Google Scholar
• MEYER UA: Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J. Biol. Med. (1996) 69:203–209.
   PubMed Web of Science ®Google Scholar
• CHEER SM, PRAKASH A, FAULDS D, LAMB HM: Pantoprazol: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs (2003) 63:101–133.
   PubMed Web of Science ®Google Scholar
• KROMER W: Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion (1995) 56:443–454.
   PubMed Web of Science ®Google Scholar
• SHIN JM, SACHS G: Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology (2002) 123:1588–1597.
   PubMed Web of Science ®Google Scholar
• SHIN JM, SACHS G: Differences in binding properties of two proton pump inhibitors on the gastric 1-1*,K*-ATPase in vivo. Biochem. Pharmacol. (2004) 68:2117–2127.
   PubMed Web of Science ®Google Scholar
• GEDDA K, SCOTT DR, BESANCON ML, LORENTZON P, SACHS G: Turnover of gastric H+,K+-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology (1995) 109:1134–1141.
   PubMed Web of Science ®Google Scholar
• REILL L, ERHARDT F, FISCHER R, HUBER R, LONDONG W: Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man. Gut (1993) 34(54):563.
   Google Scholar
• •Establishes dose-response relationship for pantoprazole on acid secretion.
   Google Scholar
• LONDONG W: Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment. Pharmacol. Ther. (1994) 8(S1):39–46.
   PubMedGoogle Scholar
• KOOP H, KULY S, FLUG M et aL: Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur. J. GastroenteroL HepatoL (1996) 8:915–918.
   PubMed Web of Science ®Google Scholar
• MUSSIG S, WITZEL L, LUHMANN R, SCHNEIDER A: Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Eur. j Gastroenterol. Hepatol. (1997) 9:599–602.
   PubMed Web of Science ®Google Scholar
• PISEGNA JR, MARTIN P, MCKEAND W, OHNING G, WALSH JH, PAUL J: Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. Am. J. GastroenteroL (1999) 94:2874–2880.
   PubMed Web of Science ®Google Scholar
• SIMON B, MULLER P, MARINIS E et al.: Effect of repeated oral administration of BY 1023/SK&F 96022- a new substituted benzimidazole derivate- on pentagastrin-stimulated gastric acid secretion and Pharmacokinetics in man. Aliment. Pharmacol. Ther. (1990) 4:373–379.
   PubMed Web of Science ®Google Scholar
• BRUNNER G, DANZ-NEEFF H, ATHMANN C et al.: Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on intragastric pH and serum gastrin in healthy volunteers. Gastroenterology (1997) 112:A78.
   Google Scholar
• HARTMANN M, THEISS U, HUBER R et al.: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment. Pharmacol. Ther. (1996) 10:359–366.
   PubMed Web of Science ®Google Scholar
• GEUS WP, MATHOT RA, MULDER PG, LAMERS CB: Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment. Pharmacol. Ther. (2000) 14:1057–1064.
   PubMedGoogle Scholar
• EHRLICH A, LUCKER PW, WIEDEMANN A, SANDER P, HUBER R, MASCHER H: Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find. Exp. Clin. Pharmacol. (1999) 21:47–51.
   PubMedGoogle Scholar
• KOOP H, KULY S, FLUG M et a/.: Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole. Gut (1994) 35(54):A79.
   Google Scholar
• HUANG JQ, GOLDWATER DR, THOMSON AB et al.: Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment. Pharmacol. Ther. (2002) 16:425–433.
   PubMedGoogle Scholar
• FLORENT C, FORESTIER S: Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur. GastroenteroL HepatoL (1997) 9:195–200.
   PubMedGoogle Scholar
• PEGHINI PL, KATZ PO, BRACY NA, CASTELL DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. GastroenteroL (1998) 93:763–767.
   PubMed Web of Science ®Google Scholar
• •Relationship of acid secretion and PPI treatment.
   Google Scholar
• KATZ PO, PAOLETTI V, BOCHENEK Wet al.: A double-blind, randomised, crossover, dose-response study of the effects of 10, 20, or 40 mg of oral pantoprazole taken once daily on intragastric pH in healthy adults. Gastroenterology (1999) 116:A208.
   Google Scholar
• KATASHIMA M, YAMAMOTO K, TOKUMA Y, HATA T, SAWADA Y, IGAT: Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole,
   Google Scholar
• •• in humans. Eur. J. Drug Metab. Pharmacokinet. (1998) 23:19–26.
   Google Scholar
• MOSSNER J, HOLSCHER AH, HERZ R, SCHNEIDER A: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment. PharmacoL Ther. (1995) 9:321–326.
   PubMed Web of Science ®Google Scholar
• CORINALDESI R, VALENTINI M, BELAICHE J, COLIN R, GELDOF H, MATER C: Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment. PharmacoL Ther. (1995) 9:667–671.
   PubMed Web of Science ®Google Scholar
• KOOP H, SCHEPP W, DAIVIMANN HG, SCHNEIDER A, LUHMANN R, CLASSEN M: Comparative trial of pantoprazole and ranitidine in the treatment of reflux oesophagitis. Results of a German multicentre study./ Clin. GastroenteroL (1995) 20:192–195.
   PubMed Web of Science ®Google Scholar
• VAN RENSBURG CJ, HONIBALL PJ, GRUNDLING HD et al.: Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment. PharmacoL Ther. (1996) 10:397–401.
   PubMed Web of Science ®Google Scholar
• WURZER H, SCHUTZE K, BETHKE T, FISCHER R, LUHMANN R, RIESENHUBER C: Efficacy and safety of patoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology (1999) 46:1809–1815.
   PubMedGoogle Scholar
• HOLTMANN G, CAIN C, MALFERTHEINER P: Gastric Helicobacter pylori infection accelerates healing of reflux oesophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology (1999) 117:11–16.
   PubMed Web of Science ®Google Scholar
• MULDER CJ, WESTERVELD BD, SMIT JM et al.: A double-blind, randomised comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance therapy: a Dutch multicentre trial. Eur. J. GastroenteroL HepatoL (2002) 14:649–656.
   PubMedGoogle Scholar
• HARTMANN M, EHRLICH A. FUDER H et al.: Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment. PharmacoL Ther. (1998) 12:1027–1032.
   Google Scholar
• PLEIN K, SCHNEIDER A. FISCHER R et al.: Efficacy and safety of sequential intravenous and oral treatment of pantoprazole in reflux esophagitis. Leber Magen Darm. (2000) 30:164–168.
   Google Scholar
• FUMAGALLI I, KLEIN M, FISCHER R: Comparison of intravenous with oral pantoprazole in symptom relief and healing of reflux esophagitis. Gastroenterology (1998) 114(S):A126.
   Google Scholar
• MOSSNER J, KOOP H, PORST H, WUBBOLDING H, SCHNEIDER k MATER C: One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Aliment. PharmacoL Ther. (1997) 11:1087–1092.
   PubMed Web of Science ®Google Scholar
• •Provides information on long-term safety of pantoprazole in GERD patients.
   Google Scholar
• KOVACS TOG, DE VAULT K, METZ D et al.: Pantoprazole prevents relaps of healed erosive esophagitis more effectively than ranitidine in gastroesophageal reflux disease patients. Am. J. GastroenteroL (1999) 94:2590.
   Google Scholar
• BOCHENEK WJ, NORTHINGTON RS, MISKA D et al.: Pantoprazole prevents relapse of healed erosive esophagitis in patients more effectively than ranitidine, regardless of baseline symptomatology. Gastroenterology (2000) 118(52):A14.
   PubMedGoogle Scholar
• ESCOURROU J, DEPREZ P, SAGGIORO A. GELDOF H, FISCHER R, MATER C: Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment. PharmacoL Ther. (1999) 13:1481–1491.
   Google Scholar
• PLEIN K, HOTZ J, WURZER H, FUMAGALLI I, LUHMANN R, SCHNEIDER k Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur. j GastroenteroL Hepatol. (2000) 12:425–432.
   PubMed Web of Science ®Google Scholar
• ADAMEK RJ, BEHRENDT J, WENZEL C: Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status; a double-blind, randomised, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur. J. GastroenteroL HepatoL (2001) 13:811–817.
   PubMedGoogle Scholar
• VAN RENSBURG CJ, HONIBALL PJ, VAN ZYL JH et al.: Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow up. Aliment. PharmacoL Ther. (1999) 13:1023–1028.
   Google Scholar
• TALLEY NJ, MOORE MG, SPROGIS A. KATELARIS P: Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med. J. Aust. (2002) 177:423–427.
   Google Scholar
• BARDHAN KD, MULLER-LISSNER S, BIGARD MA et al.: Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. Br. Med. J. (1999) 318:502–507.
   Google Scholar
• TALLEY NJ, LAURITSEN K, TUNTURI-HIHNALA H et aL: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. (2001) 15:347–354.
   PubMed Web of Science ®Google Scholar
• SCHOLTEN T, GATZ G, SANDER P et al.: On-demand therapy with pantoprazole 20 mg as effective strategy for long-term treatment in patients with mild GERD. Gut (2002) 51(53):A169.
   PubMedGoogle Scholar
• SCHOLTEN T, DEKKERS CPM, SCHÜTZE K et al.: On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD. Gut (2002) 51(53):A165.
   Google Scholar
• CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798–1810.
   PubMed Web of Science ®Google Scholar
• ••An excellent meta-analysis on the efficacyof PPIs versus H2-receptor antagonists in healing GERD; the degree of acid inhibition determines healing rates and symptom relief.
   Google Scholar
• RAMIREZ-BARBA EJ, DIBILDOX M, BERNAL F et al.: Low-dose pantoprazole (20 mg) is effective for treatment of mild reflux oesophagitis. Clin DrugInvest. (1999) 18:445–451.
   Google Scholar
• VAN ZYL JH, GRUNDLING HD, VAN RENSBURG CJ et al.: Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomised, double-blind, parallel and multicentre study. Eur. J. GastroenteroL HepatoL (2000) 12:197–202.
   Google Scholar
• DUVNJAK M, SUPANC V TROSKOT B et al.: Efficacy of pantoprazole compared with ranitidine in the treatment of reflux oesophagitis: a double-blind parallel and longitudinal comparative study. Gut (2000) 47(S2):A1274.
   Google Scholar
• DAMMANN HG, VAN KLEIST DH: Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastro-oesophageal reflux disease: multicentre, open, randomised, controlled studies. In: International clinical practice series; the German Phase IV pantoprazole programme. Domschke W (Ed.), Wells Medical Limited, Kent, UK (1997):23–29.
   Google Scholar
• MENEGHELLI UG, BOAVENTURA S, MORAES-FILHO JP et al.: Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux oesophagitis and the influence of Helicobacter pylori infection on healing rate. Dis. Esophagus (2002) 15:50–56.
   PubMedGoogle Scholar
• ARMSTRONG D, PARE. P, PERICAK D, PYZYK M: Canadian Pantoprazole GERD Study Group: Symptom relief in gastroesophageal reflux disease: a randomised, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis and endoscopy-negative reflux disease. Am. J. GastroenteroL (2001) 96:2849–2857.
   PubMed Web of Science ®Google Scholar
• BOCHENEK WJ, and the PANTOPRAZOLE GERD US STUDY GROUP: Pantoprazole heals erosive esophagitis more effectively and provides greater symptomatic relief than placebo or nizatidine in gastro-oesophageal reflux disease (GERD) patients. Gastroenterology (1999) 116:A125.
   Google Scholar
• FITTON Y, WISEMAN L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs (1996) 51:460–482.
   Google Scholar
• GARNER A, FADLALLAH H: Pantoprazole: a new and more specific proton pump inhibitor. Expert Opin. Investig Drugs (1997) 6:885–893.
   PubMedGoogle Scholar
• BARDHAN KD: Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs Today (1999) 35:773–808.
   PubMed Web of Science ®Google Scholar
• KASPARI S, BIEDERMANN A, MEY J: Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion (2001) 63:163–170.
   Google Scholar
• PARE P, ARMSTRONG D, PERICAK D, PYZYK M: Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomised, double blind comparative study with nizatidine. j Clin. GastroenteroL (2003) 37:132–138.
   PubMedGoogle Scholar
• KAHRILAS PJ, FENNERTY MB, JOELSSON B: High- versus standard dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am. J. GastroenteroL (1999) 94:92–97.
   PubMed Web of Science ®Google Scholar
• FARLEY A, WRUBLE LD, HUMPHRIES TJ: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomised clinical trial. Rabeprazole Study Group Am. J. Gastroenterol. (2000) 95:1894–1899.
   PubMed Web of Science ®Google Scholar
• ALTORKI NK, SKINNER DB: Pathophysiology of gastroesophageal reflux. Am. J. Med. (1989) 86:685–689.
   PubMedGoogle Scholar
• LACHMAN L, HOWDEN CW: Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am. J. GastroenteroL (2000) 95:57–61.
   PubMed Web of Science ®Google Scholar
• WILDER-SMITH CH, ERNST T, GENNONI M, ZEYEN B, HALTER F, MERKI H: Tolerance to oral H2-receptor antagonists. Dig. Dis. Sci. (1990) 35:976–983.
   PubMed Web of Science ®Google Scholar
• BARDHAN KD, CHERIAN P et aL: Pantoprazole in aggressive or refractory acid-peptic disease. Gastroenterology (1996) 110:A57.
   Web of Science ®Google Scholar
• BARDHAN KD, VAN RENSBURG C: Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment. Pharmacol. Ther. (2001) 15:1585–1591.
   PubMedGoogle Scholar
• LACEVIC N, BRATOVIC I, VUKOBRAT-BIJEDIC Z: Clinical efficacy of pantoprazole 20 mg and omeprazole 20 mg in treatment of mild esophageal reflux disease. Gut (2001) 51(53):A166.
   Google Scholar
• VICARI F, BELIN J, MAREK L: Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: results of a French multicentric double-blind comparative trial. Gastroenterology (1998) 114(52):A324.
   PubMedGoogle Scholar
• KORNER T, SCHUTZE K, VAN LEENDERT RJ et al.: Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagits. Digestion (2003) 67:6–13.
   Google Scholar
• DUPAS JL, HOUCKE P, SAMOYEAU R, and the FRENCH COLLABORATIVE PANTOPRAZOLE STUDY GROUP: Pantoprazole versus lansoprazole in French patients with reflux esophagitis. GastroenteroL Clin. Biol. (2001) 25:245–250.
   PubMedGoogle Scholar
• FRAZZONI M, DE MICHELI E, GRISENDI A, SAVARINO V: Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole versus pantoprazole. Aliment. PharmacoL Ther. (2003) 17:235–241.
   PubMedGoogle Scholar
• GILLESSEN A, BEIL W, MODLIN IM,GATZ G, HOLE U: 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J. Clin. GastroenteroL (2004) 38:332–340.
   PubMed Web of Science ®Google Scholar
• EISSELE R, GATZ G, HOLE U: Equivalent efficacy of pantoprazole 40 mg and esomeprazole 40 mg in patients with GERD. Can. J. GastroenteroL (2002) 16(S):95A.
   Google Scholar
• MINER P, KATZ PO, CHEN Y, SOSTEK M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. GastroenteroL (2003) 98:2616–2620.
   PubMed Web of Science ®Google Scholar
• SCHOLTEN T, GATZ G, HOLE U: Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment. PharmacoL Ther. (2003) 18:587–594.
   PubMed Web of Science ®Google Scholar
• LAURITSEN K, JAUP B, CARLING L et al.: Comparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERD. Gut (2000) 47(53):A60.
   Google Scholar
• JASPERSEN D, DIEHL KL, SCHOEPPNER H, GEYER P, MARTENS E: A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment. PharmacoL Ther. (1998) 12:49–52.
   PubMedGoogle Scholar
• NETZER P, GUT A. BRUNDLER R, GAIA C, HALTER F, INAUEN W: Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment. PharmacoL Ther. (2001) 15:1375–1384.
   PubMedGoogle Scholar
• CHAMPION G, RICHTER JE, VAEZI MF, SINGH S, ALEXANDER R: Duodenogastroesophageal reflux: relationship to pH and importance in Barett's esophagus. Gastroenterology (1994) 107:747–754.
   PubMed Web of Science ®Google Scholar
• MARSHALL RE, ANGGIANSAH A. MANIFOLD DK, OWEN WA, OWEN WJ: Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut (1998) 43:603–606.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN AE, WALTERS JK, KATONA BG, SOUNEY PE, LEVINE D: A review of omeprazole use in the treatment of acid-related disorders in children. Clin. Ther. (2001) 23:660–679.
   PubMedGoogle Scholar
• FONKALSRUD EW, AMENT ME: Gastroesophageal reflux in childhood. Cuff. Probi. Surg. (1996) 33:1–70.
   PubMed Web of Science ®Google Scholar
• MADRAZO-DE LA GARZA A, DIBILDOX M, VARGAS A, DELGADO J, GONZALEZ J, YANEZ P: Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J. Pediatr. Gastroenterol Nutr. (2003) 36:261–265.
   PubMedGoogle Scholar
• •Describes the safety and efficacy of pantoprazole in children with erosive GERD.
   Google Scholar
• COLLEN MJ, ABDULIAN JD, CHEN YK: Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy. Am. J. Gastroenterol (1995) 90:1053–1057.
   PubMedGoogle Scholar
• •Clinical presentation and treatment strategies of reflux disease in elderly patients.
   Google Scholar
• RICHTER JE: Gastroeosphageal reflux disease in the older patient: presentation, treatment and complications. Am. J. Gastroenterol (2000) 95:368–373.
   PubMed Web of Science ®Google Scholar
• •Describes the clinical spectrum of GERD in elderly patients.
   Google Scholar
• BREUEL HP, HARTMANN M, BONDY S et al.: Pantoprazole in the elderly: No dose-adjustement. Gut (1994) 35(54):1161.
   Google Scholar
• PILOTTO A, LEANDRO G, FRANCESCHI M, and the AGEING AND ACID-RELATED DISEASE STUDY GROUP: Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment. PharmacoL Ther. (2003) 17:1399–1406.
   PubMed Web of Science ®Google Scholar
• BISHOP A, ROMANSKA H, POLAK J et al.: Effect of long-term maintenance with pantoprazole on serum gastrin and histology parameters in severe acid-peptic disease. Gastroenterology (1998) 114(S):A75.
   Google Scholar
• BRUNNER G: Clinical safety and route of administration of pantoprazole. Ann. GastroenteroL Ilepatol (1997) 33:46.
   Google Scholar
• ATHMANN C, MANDER I, BRUNNER G et al.: Histology and safety parameters during long-term maintenance with pantoprazole in severe acid-peptic disease. Gastroenterology (1998)114(S):A60.
   Google Scholar
• HARTMANN N, HUBER R, BLIESATH H et al.: Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int. J. Clin. PharmacoL Ther. (1995) 33:481–485.
   PubMedGoogle Scholar
• ANDERSSON T: Pharmacokinetic, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. (1996) 31:9–28.
   Google Scholar
• KOVACS TOG, DOHERTY E, NORTHINGTON RS et al: The effect of Helicobacter pylori on symptoms and healing of erosive esophagitis during pantoprazole therapy. Gastroenterology (2000) 118:A1261.
   PubMedGoogle Scholar
• CALLEJA J, SEBASTIAN J, SUAREZ M et al.: Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse during treatment with pantoprazole. j Gastroenterol Hepatol (2002) 17(S):A216.
   Google Scholar
• VERDU EF, ARMSTRONG D, FRASER R et al.: Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut (1995) 36:539–543.
   PubMed Web of Science ®Google Scholar
• LABENZ J, TILLENBURG B, PEITZ U et al.: Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology (1996) 10:725–732.
   Google Scholar
• LABENZ J, MALFERTHEINER P: Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut (1997) 41:277–280.
   PubMed Web of Science ®Google Scholar
• LABENZ J, BLUM AL, BAYERDORFFER E, MEINING A, STOLTE M, BORSCH G: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology (1997) 112:1442–1447.
   PubMed Web of Science ®Google Scholar
• CARLSSON R: Gastroesophageal reflux disease: a study of pathophysiology clinical diagnosis and management (thesis). Gotheburg: University of Gotheburg (1998).
   Google Scholar
• O'CONNOR HJ, CUNNANE K: Helicobacter pylori and gastro-oesophageal reflux disease: a prospective study. Jr. J. Med. Sci. (1994) 163:369–373.
   Google Scholar
• DE KOSTER E, KUIPERS EJ: Reflux and Helicobacter pylori. Curr. Opin. GastroenteroL (1997) 13:43–47.
   Google Scholar
• XIA HH, TALLEY NJ: Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle. Am. J. GastroenteroL (1998) 93:394–400.
   PubMedGoogle Scholar
• SCHENK BE, KUIPERS EJ, KLINKENBERG-KNOL EC, ESKES SA, MEUWISSEN SGM: H. pylori, GERD and the efficacy of omeprazole therapy. Gastroenterology (1997) 112:A282.
   Google Scholar
• LOGAN RP, WALKER MM, MISIEWICZ JJ, GUMMETT PA, KARIM QN, BARON JH: Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut (1995) 36:12–16.
   PubMed Web of Science ®Google Scholar
• KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOL EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl. J. Med. (1996) 334:1018–1022.
   PubMed Web of Science ®Google Scholar
• KLINKENBERG-KNOL EC, NELIS F, DENT Jet al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 118:661–669.
   Google Scholar
• LUNDELL H, HAVU N, ANDERSSON A et al.: Gastritis development and acid suppression therapy revisited: results of a randomised clinical study with long-term follow-up. Gastroenterology (1997) 112:A28.
   Web of Science ®Google Scholar
• PARSONNET J: Helicobacter pylori and gastric cancer. Gastroenter. Clin. North America (1993) 22:89–104.
   PubMed Web of Science ®Google Scholar
• FORMAN D, GRAHAM DY: Impact of Helicobacter pylori on society-role for a strategy of search and eradicate. Aliment. Pharmacol Ther. Suppl (2004) 1:17–20.
   Google Scholar
• SIPPONEN P, HYVAREN H: Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J. Gastroenterol. (1993) 196:3–6.
   Google Scholar
• CORREA P, PIAZUELO MB, CAMARGO MC: The future of gastric cancer prevention. Gastric Cancer (2004) 7:9–16.
   PubMedGoogle Scholar
• NORMARK S, NILSSON C, NORMARK BH, HORNEF MW: Persistent infection with Helicobacter pylori and the development of gastric cancer. Adv. Cancer Res. (2003) 90:63–89.
   PubMedGoogle Scholar
• SUERBAUM S, MICHETTI P: Helicobacter Infection. N Engl. Med. (2002) 347:1175–1186.
   PubMed Web of Science ®Google Scholar
• ••Excellent summary on H pylori infection:from the discovery to the cure of peptic ulcer disease.
   Google Scholar
• LINS RL, DE CLERCQ I, HARTMANN M et al.: Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment. Gastroenterology (1994) 106:A126.
   Web of Science ®Google Scholar
• VAN HOUT BA, KLOK RM, BROUWERS JR, POSTMA MJ: A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. Clin. Ther. (2003) 25:635–646.
   PubMedGoogle Scholar